Advertisement

Topics

Keytruda/chemo combo cut risk of death in NSCLC

06:12 EDT 17 Apr 2018 | PharmaTimes

MSD has unveiled further data from a trial showing that a combination of Keytruda and chemotherapy significantly improved overall survival in patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).

Original Article: Keytruda/chemo combo cut risk of death in NSCLC

NEXT ARTICLE

More From BioPortfolio on "Keytruda/chemo combo cut risk of death in NSCLC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...